Market capitalization | $36.19b |
Enterprise Value | $48.18b |
P/E (TTM) P/E ratio | 26.15 |
EV/FCF (TTM) EV/FCF | 24.57 |
EV/Sales (TTM) EV/Sales | 3.15 |
P/S ratio (TTM) P/S ratio | 2.36 |
P/B ratio (TTM) P/B ratio | 5.20 |
Revenue growth (TTM) Revenue growth | 3.17% |
Revenue (TTM) Revenue | $15.31b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
28 Analysts have issued a IQVIA forecast:
28 Analysts have issued a IQVIA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15,314 15,314 |
3%
3%
|
|
Gross Profit | 4,259 4,259 |
6%
6%
|
|
EBITDA | 3,291 3,291 |
7%
7%
|
EBIT (Operating Income) EBIT | 2,164 2,164 |
13%
13%
|
Net Profit | 1,405 1,405 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 87,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.